210 related articles for article (PubMed ID: 20491634)
1. PDE5 inhibitors and their applications.
Giovannoni MP; Vergelli C; Graziano A; Dal Piaz V
Curr Med Chem; 2010; 17(24):2564-87. PubMed ID: 20491634
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
3. Tadalafil for benign prostatic hyperplasia.
Drug Ther Bull; 2013 Aug; 51(8):93-6. PubMed ID: 23949822
[TBL] [Abstract][Full Text] [Related]
4. Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
Zhang WH; Zhang XH
Asian J Androl; 2016; 18(5):723-31. PubMed ID: 26620458
[TBL] [Abstract][Full Text] [Related]
5. Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5.
Chau Y; Li FS; Levsh O; Weng JK
PLoS One; 2019; 14(9):e0222803. PubMed ID: 31539416
[TBL] [Abstract][Full Text] [Related]
6. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
Yan H; Zong H; Cui Y; Li N; Zhang Y
J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
[TBL] [Abstract][Full Text] [Related]
8. Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach.
Ongaro A; Zagotto G; Memo M; Gianoncelli A; Ribaudo G
Nat Prod Res; 2021 May; 35(10):1648-1653. PubMed ID: 31140295
[TBL] [Abstract][Full Text] [Related]
9. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
Xu Z; Jia RP
Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
[TBL] [Abstract][Full Text] [Related]
10. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
[TBL] [Abstract][Full Text] [Related]
11. PDE5 inhibitors for LUTS.
Mouli S; McVary KT
Prostate Cancer Prostatic Dis; 2009; 12(4):316-24. PubMed ID: 19687801
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
Ioakeimidis N; Kostis JB
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):53-64. PubMed ID: 24281316
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
Wang C
Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
[TBL] [Abstract][Full Text] [Related]
15. Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses.
Mostafa T
J Sex Med; 2008 Nov; 5(11):2502-18. PubMed ID: 18761597
[TBL] [Abstract][Full Text] [Related]
16. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
17. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
[TBL] [Abstract][Full Text] [Related]
18. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Zhao C; Kim SH; Lee SW; Jeon JH; Kang KK; Choi SB; Park JK
BJU Int; 2011 Jun; 107(12):1943-7. PubMed ID: 21054754
[TBL] [Abstract][Full Text] [Related]
19. [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology].
Becker AJ; Uckert S; Stief CG
Urologe A; 2008 Dec; 47(12):1582-7. PubMed ID: 18854969
[TBL] [Abstract][Full Text] [Related]
20. The unexpected evolution of basic science studies about cyclic nucleotide action into a treatment for erectile dysfunction.
Corbin J
J Biol Chem; 2015 Jan; 290(3):1374-88. PubMed ID: 25505249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
